Print

AVEG 202/HIVNET 014

A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 with or without HIV-1 SF-2 RGP-120 in HIV-1 Uninfected Adult

Trial Details:

II Completed
National Institute of Allergy and Infectious Diseases (NIAID) May 22, 1997
ALVAC-HIV MN120TMG strain (vCP205),rgp120/HIV-1 SF-2 Canarypox Env gp120, TM gp41, gag, protease B MN/LAI;  Protein Env gp120 B SF-2
ALVAC-HIV MN120TMG strain (vCP205) Viral Vector - Pox
rgp120/HIV-1 SF-2 Protein
USA 420
NCT00000871
https://clinicaltrials.gov/show/NCT00000871